Contrasting Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and X4 Pharmaceuticals (NASDAQ:XFOR)

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Profitability

This table compares Lakefront Biotherapeutics American Depositary Shares and X4 Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
X4 Pharmaceuticals	-568.80%	-63.05%	-36.89%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Lakefront Biotherapeutics American Depositary Shares and X4 Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	0	5	3	1	2.56
X4 Pharmaceuticals	1	1	4	0	2.50

Lakefront Biotherapeutics American Depositary Shares presently has a consensus price target of $37.00, suggesting a potential upside of 25.34%. X4 Pharmaceuticals has a consensus price target of $11.25, suggesting a potential upside of 287.93%. Given X4 Pharmaceuticals’ higher possible upside, analysts clearly believe X4 Pharmaceuticals is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Risk and Volatility

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500.

Earnings and Valuation

This table compares Lakefront Biotherapeutics American Depositary Shares and X4 Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$990.57 million	1.96	$363.05 million	($1.41)	-20.94
X4 Pharmaceuticals	$15.85 million	18.14	-$79.20 million	($1.20)	-2.42

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than X4 Pharmaceuticals. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are owned by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by company insiders. Comparatively, 1.1% of X4 Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Lakefront Biotherapeutics American Depositary Shares beats X4 Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

About Lakefront Biotherapeutics American Depositary Shares

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company’s pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.